AVE 16.7% 0.3¢ avecho biotechnology limited

EARNINGS PREVIEW: Europe Pharma's 3Q Results Set To be Mixed....

  1. 2,006 Posts.
    EARNINGS PREVIEW: Europe Pharma's 3Q Results Set To be Mixed.

    October 15, 2010

    TAKING THE PULSE: European pharmaceutical companies are set to present mixed third-quarter performances in coming days, with analysts and investors expecting players to elaborate further on planned restructuring and how some will handle imminent sales declines due to patent expiries in coming years.

    All face regulatory hurdles and pricing pressures following health care reforms in the U.S. and Europe that leave many few options other than to pursue new avenues of growth and adapt to the post-blockbuster era, making sense of, and hopefully profiting from, a vast array of new scientific breakthroughs and technologies.

    Link:
    http://www.nasdaq.com/aspx/stock-market-news-story.aspx?storyid=201010151018dowjonesdjonline000455&title=earnings-preview-europe-pharmas-3q-results-set-to-be-mixed

 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
-0.001(16.7%)
Mkt cap ! $7.923M
Open High Low Value Volume
0.3¢ 0.3¢ 0.3¢ $3.226K 1.116M

Buyers (Bids)

No. Vol. Price($)
52 92468918 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 76402411 25
View Market Depth
Last trade - 12.50pm 06/09/2024 (20 minute delay) ?
AVE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.